We have located links that may give you full text access.
Cost-Utility of Anti-VEGF Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Ophthalmology Retina 2020 September 29
OBJECTIVE: To evaluate the cost-utility of treatment for macular edema in central retinal vein occlusion (CRVO) using intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents bevacizumab, ranibizumab, and aflibercept.
DESIGN: A decision analysis model of cost-utility PARTICIPANTS: Data from study participants in the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) study.
METHODS: A decision analysis of a disease simulation model was used to calculate comparative cost-utility of intravitreal bevacizumab (IVB), ranibizumab (IVR), and aflibercept (IVA) for the treatment of macular edema associated with CRVO based on data from LEAVO study. Center for Medicare and Medicaid Services data were used to calculate associated modeled costs in a hospital/facility based and non-facility setting from a third-party payer perspective, and societal costs were also calculated. Cost-utility was calculated based on the preserved visual utility during the 2 years of the study and also by estimating utility for the expected lifetime.
MAIN OUTCOME MEASURES: Cost of treatment, cost/QALY, incremental cost-effectiveness ratio (ICER) RESULTS: From the third-party payer perspective, the estimated life-time cost/QALY in the facility (non-facility) setting was $39,325 ($17,944) for IVB, $114,095 ($92,653) for IVR, and $78,935 ($63,270) for IVA. From the societal perspective the estimated life-time cost/QALY in the facility setting was $52,754 for IVB, $128,242 for IVR, and $86,262 for IVA. The incremental cost-effectiveness ratio (ICER) of IVA compared to IVB was $153,633/QALY from the third-party facility setting and ($152,992/QALY) from the societal perspective. The use of IVB compared to IVR and IVA compared to IVR were cost-saving interventions (ICER<0) irrespective of the perspective or setting.
CONCLUSIONS: In the treatment of macular edema in CRVO, IVB yields the best cost-utility among the three anti-VEGF agents modeled. IVA maintains acceptable lifetime cost/QALY, while having a favorable cost-utility compared to IVR.
DESIGN: A decision analysis model of cost-utility PARTICIPANTS: Data from study participants in the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) study.
METHODS: A decision analysis of a disease simulation model was used to calculate comparative cost-utility of intravitreal bevacizumab (IVB), ranibizumab (IVR), and aflibercept (IVA) for the treatment of macular edema associated with CRVO based on data from LEAVO study. Center for Medicare and Medicaid Services data were used to calculate associated modeled costs in a hospital/facility based and non-facility setting from a third-party payer perspective, and societal costs were also calculated. Cost-utility was calculated based on the preserved visual utility during the 2 years of the study and also by estimating utility for the expected lifetime.
MAIN OUTCOME MEASURES: Cost of treatment, cost/QALY, incremental cost-effectiveness ratio (ICER) RESULTS: From the third-party payer perspective, the estimated life-time cost/QALY in the facility (non-facility) setting was $39,325 ($17,944) for IVB, $114,095 ($92,653) for IVR, and $78,935 ($63,270) for IVA. From the societal perspective the estimated life-time cost/QALY in the facility setting was $52,754 for IVB, $128,242 for IVR, and $86,262 for IVA. The incremental cost-effectiveness ratio (ICER) of IVA compared to IVB was $153,633/QALY from the third-party facility setting and ($152,992/QALY) from the societal perspective. The use of IVB compared to IVR and IVA compared to IVR were cost-saving interventions (ICER<0) irrespective of the perspective or setting.
CONCLUSIONS: In the treatment of macular edema in CRVO, IVB yields the best cost-utility among the three anti-VEGF agents modeled. IVA maintains acceptable lifetime cost/QALY, while having a favorable cost-utility compared to IVR.
Full text links
Related Resources
Trending Papers
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Bronchiectasis management in adults: state of the art and future directions.European Respiratory Journal 2024 May 24
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.Biomedicines 2024 April 31
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app